Member Info for ROCKZ

Wood said the genomics space is also set to hit escape velocity.

“DNA sequencing is going to introduce science into healthcare decision making for the first time,” said Wood. “We can honestly say that until now more than half of all healthcare decisions were in some part made through guesses or experiences. Now we’re going to have the data.”

ARK’s Genomics ETF has big bets on Exact Sciences, which makes up nearly 5% of the ETF, and Invitae. CRISPR Therapeutics is another major holding in the ETF.

“We’re going to be able to cure diseases that we never thought it would be possible to cure, including cancer,” said Wood.

Shares of ARK Innovation are up 2.5% this year and shares of ARK Genomic Revolution are up less than 1% in 2021.

https://www.bionews.org.uk/page_95613

Feels like a bearish week following that big bonus for GC.
On a positive note, maybe he’s one step ahead of the game in terms of DNA sequencing and the purchase of a biobank of blood samples in Sardinia.
Cathie Wood has also tipped DNA sequencing as the next big thing.
From an historical article showing an interview with KS: But the company did hit controversy last year when it paid £217,000 for a biobank of blood samples from 13,000 residents living in a province of Sardinia with a high proportion of centenarians - almost 50 times greater than the UK rate.
Tiziana says the database could hold the keys to new drugs and diagnostic tests but local politicians and campaigners say the purchase was unethical because the people did not consent to their data, collected by local physicians, being used by a for-profit firm.
“If we can isolate the DNA from these samples and do the sequencing, then we would have a database which would be a gold mine to dig into different diseases and it could be very useful,” says Shailubhai. “The scientific rationale is very powerful.”
He shows no sign of slowing down or losing his enthusiasm, adding: “I tell people that the biotech industry is a roller coaster ride. If you are able to go through it, there can be huge rewards. But you have to hold on for the whole ride.”

Is GC just protecting his interests from a low ball takeover offer or has he got something up his sleeve himself? Either way, it’s a positive for shareholders at these current low levels.

I’m saying the bottoms in.
Just brought 2683 at 73.74p.
Don’t forget Gabrielle brought a load more shares in December at 78p, that’s a good sign to me.

Let’s hope the interviews are more clear and concise moving forward.
I thought they were pretty good last year but GC and KS have regressed in the messages they are sending out to investors.
It would be nice to know if GC will be inline for another bonus the next time he completes a raise of funds which will probably be around the £2 mark again IMO.

Mr Wong, you know it’s Accustem, not Aquastem?
I’m guessing that’s tongue in cheek as most are under water here!

I agree Sang. I’ve complained aswell but know it will make no difference whatsoever.

Managed to get a 1261 shares top up over the phone in the end but surely the market shouldn’t me so illiquid for relatively small amounts when the share price is in the red again?

Strange dealing today. NT to buy anything and can’t sell anything over £1000?

Anyone who is able to listen, any live notes in the meantime would be most welcome.

For those with an active Clubhouse app the chat with Gabrielle is at 3pm GMT.
I have only registered for the app yesterday so it hasn’t activated in time but I have spoken to Tara who is going to post notes later on.

I’ve just had some of your shares, just added 1284.
Good luck elsewhere.

No feathers ruffled here. I’m looking to top up tomorrow.
We all try and find the bottom but it can be quite seldom for many of us.

Nightmare, I doubt the other pharma companies you are invested in are providing monoclonal antibodies as a form of treatment in nasal and oral administration form?...with the patents to back it up.
Therein lies the value.

This SP is taking a bit of a kicking at the moment but we’re not alone, look at SNG.
I use PRVB as a good comparison which has also had a rough ride in the last few months. Market cap of PRVB is $456M. Is their pipeline any better than TILS and do they have the platform technology of TILS?
NO.
I’m holding tight and staying patient although understand how punishing it must be for some, especially those with a higher average.

No point coming on here to lie, I’ve got better things to do fella.
Phone the Tiziana office yourself, Hana is very helpful and happy to answer questions within her scope. She will confirm that all Phase2 trials are on schedule and starting shortly. We both know she can’t give anymore than that.
I’m assuming this doesn’t suit your agenda?

Depends on news...announcement of Phase 2 trials due at anytime. At some point we are going to see the end of the 80’s and 90’s as the company takes the next leg up.

No worries MRK, she wasn’t able to confirm dates obviously but we can expect 3 x RNS’s in the not too distant future to confirm start dates for the trials.

I have spoken to the company today as I was looking for clarification on the trial status.
Like a few others, I was uncertain regarding KS saying ‘we are in Phase2 trials for Crohns and MS’.
The trials haven’t started yet but are starting soon and everything is on schedule and going to plan.
Slight mis-use of language really but nothing to worry about and no intention to mis-lead anyone.